
Stipple Bio
Biotech · Oncology · Pharma
Eli Lilly signs $5.9B oncology deal with biotech Stipple Bio
November 16, 2026
Epitope-level targeting could unlock cancer markers too risky for today's precision therapies to touch, if the science holds.
- Eli Lilly signed a strategic oncology research collaboration and license agreement with Stipple Bio worth up to $5.9 billion in milestone payments, plus an upfront payment and equity stake.
- Stipple Bio, a Cambridge, Mass. biotech co-founded by Fred Hutch's Aaron Ring and UCSF's Aashish Manglik, uses its Pointillist platform to find cancer-specific cell-surface epitopes.
- Lilly secures exclusive worldwide rights to develop and commercialize any products arising from the collaboration, which spans multiple undisclosed modalities and indications.
- Stipple raised a $100 million Series A in April, giving it cash runway into 2029 as it independently advances its own pipeline alongside the Lilly work.
- Stipple's own lead candidate, antibody-drug conjugate STP-100 for solid tumors including pancreatic cancer, is slated to enter Phase 1 trials in early 2027.
- The pact extends Lilly's oncology push beyond blockbusters Verzenio and Jaypirca as the drugmaker diversifies beyond its diabetes and obesity franchise.
- By targeting epitopes unique to tumor cells rather than broadly overexpressed proteins, Stipple's approach could open up drug targets long avoided due to toxicity in healthy tissue.